NCT05893407 Brain PERfusion Evaluation by Contrast-Enhanced UltraSound
| NCT ID | NCT05893407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Cerebral Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-07-21 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2023-07-21 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims : * to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound. * to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 * Intensive care unit admission for acute brain injury * Proven acute brain injury by CT and/or MRI * Requiring a contrast ultrasound imaging * Informed consent of patient or relative Exclusion Criteria: * Pregnancy * Not sufficient temporal window * Contraindications to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension \> 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue® * Patient on State Medical Assistance
Contact & Investigator
Romain BARTHELEMY, MD
PRINCIPAL INVESTIGATOR
AP-HP Lariboisière Hospital, Department of Anaesthesia and Intensive Care
Frequently Asked Questions
Who can join the NCT05893407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05893407 currently recruiting?
Yes, NCT05893407 is actively recruiting participants. Contact the research team at romain.barthelemy@aphp.fr for enrollment information.
Where is the NCT05893407 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05893407 clinical trial?
NCT05893407 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Romain BARTHELEMY, MD at AP-HP Lariboisière Hospital, Department of Anaesthesia and Intensive Care. The trial plans to enroll 60 participants.